Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

Rachna T. Shroff, MD, MS
Published: Tuesday, Oct 15, 2019



Rachna T. Shroff, MD, MS, chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma. 
 
In intrahepatic cholangiocarcinoma, targetable mutations account for about 30% of all patients, says Shroff. Alterations in IDH1 make up about 20% of that population while FGFR2 fusions comprise about 10% to 15% of these patients. 
 
Though rarer, BRAF mutations, HER2 amplifications or alterations, and homologous recombination deficiencies are also potentially actionable targets. 
 
Extrahepatic cholangiocarcinoma differs in that IDH1 mutations and FGFR2 fusions are not as frequently expressed, while HER2 amplifications are more common. As in intrahepatic disease, BRAF is also seen, albeit in a small subset of patients. 
SELECTED
LANGUAGE


Rachna T. Shroff, MD, MS, chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma. 
 
In intrahepatic cholangiocarcinoma, targetable mutations account for about 30% of all patients, says Shroff. Alterations in IDH1 make up about 20% of that population while FGFR2 fusions comprise about 10% to 15% of these patients. 
 
Though rarer, BRAF mutations, HER2 amplifications or alterations, and homologous recombination deficiencies are also potentially actionable targets. 
 
Extrahepatic cholangiocarcinoma differs in that IDH1 mutations and FGFR2 fusions are not as frequently expressed, while HER2 amplifications are more common. As in intrahepatic disease, BRAF is also seen, albeit in a small subset of patients. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x